Naslov
Effect of L-carnitine therapy on erythropoiesis-stimulating agents, erythropoietin resistance index and anemia in patients on maintenance hemodialysis

Autori
Dorčić, Gordan ; Bubić, Ivan ; Vujičić, Božidar ; Šimunović, Filip ; Devčić, Bosiljka ; Rački, Sanjin

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
Nephro Update 2018

Mjesto i datum
Budimpešta, Mađarska, 05.10.2018. - 06.10.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
L-carnitine, erythropoietin, anemia, hemodialysis

Sažetak
OBJECTIVE. Anemia is a common complication among patients on maintenance hemodialysis (HD) which if left untreated increases risk for cardiovascular events and death. The objective of this study was to investigate effect of L- Carnitine (LC) therapy on anemia and erythropoiesis-stimulating agents (ESA) therapy in HD patients. METHODS. We included patients in Department of Nephrology, Dialysis and Kidney Transplantation, Clinical Hospital Centre Rijeka, that have been on HD for three months least, starting from June, 2017. and allocated them into two groups – receiving LC therapy and without LC. We analyzed weekly ESA dose, erythropoietin resistance index (ERI), serum levels of hemoglobin and erythrocites. Measurements were made at the baseline and at the follow up, 6 months later. RESULTS. We analyzed 23 patients in LC group and 21 patient in non-LC group [14(60%)/12(55%) males, 7(30%)/5(24%) diabetic, mean age 62, 5 ± 9, 35 / 66 ± 10, 97 years]. There was no statistically significant difference in demographic parameters between the groups, at the baseline. At the follow up after six months, in comparison to non-LC group, LC group had significant decrease in required ESA therapy (from 95% to 55% patients, p<0, 01), mean weekly ESA dose (p<0, 02), and mean ERI (p<0, 05), There was no significant difference in serum erythrocites and hemoglobine levels between the groups at the follow up. CONCLUSIONS. Our study showed that additional LC therapy in HD patients decreases requirement of weekly ESA dosage while also decreasing ERI and maintaining adequate levels of serum hemoglobin and erythrocytes. Further investigations in greater number of patients are needed.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA